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1. Introduction  
Gene therapy is the use of genes or DNA for the treatment of diseases. For the treatment of 
inherited disorders, DNA carrying a functional gene is introduced into the cells of a patient 
to reverse the defect of the corresponding malfunctioning endogenous gene. Previous 
genetic characterization of the disease and cloning of the gene that causes it are necessary. In 
most cases, the cDNA of the therapeutic gene is cloned into a bacterial plasmid under the 
control of a strong heterologous promoter (often of viral origin). However, such constructs, 
called mini-genes, lack introns, promoters, enhancers, and long-range controlling elements 
that precisely control the temporal and spatial expression of the endogenous gene.  
For gene therapy of some diseases it is important to achieve expression of the therapeutic 
gene at specific levels. Expression at lower levels than normal might not be sufficient to 
correct the defect and at higher levels could result in undesirable effects. In other cases, 
tissue-specific expression may be very important. The elements responsible for controlled 
and tissue-specific expression of a gene usually lie within the introns and the sequences 
before and after the gene. Therefore, the use of genomic constructs which contain the introns 
and flanking DNA of the therapeutic gene is expected to be more effective than that of mini-
gene constructs in gene therapy for certain genetic diseases where precise levels of the gene 
product are required (reviewed by (Pérez-Luz & Díaz-Nido, 2010)). Bacterial Artificial 
Chromosomes (BACs), originating from the human genome project, contain genomic loci of 
approximately 180 kb on average and cover the entire human genome (Osoegawa et al., 
2001). These sequenced BACs can accommodate most genes along with their regulatory 
elements and can serve as tools in gene therapy using genomic constructs.  
Gene therapy as a modern therapeutic tool should provide a permanent cure to the patient 
by long-term maintenance and expression of the administered gene. This can be achieved 
either by integration of the transgene into the natural chromosomes or by other mechanisms 
for its replication and nuclear retention.  
One of the most important aspects of gene therapy is the choice of the vector that will 
deliver and express the corrective gene in the appropriate cells. Current vectors fall into two 
categories: viral and non-viral. Apart from determining the method of delivery, the type of 
vector also determines the fate of the therapeutic gene within the cells. For instance, the 
vector may have the ability to remain extra-chromosomally. Non-viral artificial chromosome 
vectors and adeno-associated viral, adenoviral, Herpes viral and EBV vectors are all 
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examples of this type. In contrast, retroviral and lentiviral vectors integrate into the host 
genome (reviewed by (Verma & Weitzman, 2005)).  
The majority of current gene therapy approaches are based on viral vectors due to their 
highly efficient delivery into cells. There are some examples of successful viral gene therapy 
clinical trials which had impressive clinical benefit for the patients (Cavazzana-Calvo et al., 
2000). However, viral gene therapy has been subjected to criticism mostly because of two 
unfortunate events. In one case a patient with ornithine transcarbamylase deficiency treated 
with an adenoviral vector died due to provocation of an immune response (Raper et al., 
2003). This death raised a safety issue that is hard to address, as human immune responses 
cannot be predicted pre-clinically. In another case, SCID-X1 patients treated with a retroviral 
vector developed a leukemia-like condition due to disruption of an endogenous oncogene 
by integration of the vector (Hacein-Bey-Abina et al., 2003a, 2003b). Since vector integration 
is random and uncontrollable, insertional mutagenesis is a general problem that all 
integrating viral vectors have. 
Ideally, vectors suitable for gene therapy should meet four criteria. Firstly, they should be 
safe. In this context all vectors that arise from non-human sequences might cause adverse 
immune responses and are not suitable. Additionally, vectors that integrate into the host 
genome at random positions are also unsafe. Secondly, they could be efficiently delivered 
into cells. Viral vectors have an advantage in this respect but recently developed physical 
methods for non-viral DNA delivery (Reviewed by (Al-Dosari & Gao, 2009)) might prove to 
be equally effective. Thirdly, they should remain permanently in the cells and provide long-
term expression of the transgene they carry. As random integration is excluded due to the 
first criterion, extra-chromosomally retained or site-specific integrating vectors might be an 
alternative solution. Fourthly, their cloning capacity should be high enough to allow them to 
carry fully functional genes with appropriate regulatory elements. Such intact genes, or gene 
clusters, can be very large and conventional molecular biology techniques will be 
inadequate for manipulating them. New technologies are therefore needed.  
This chapter will focus on non-viral vectors containing entire genomic loci rather than mini-
genes. The necessity for using these constructs will become clear through several examples 
of preclinical work with integrating vectors conferring position independent expression 
from large transgenes. Key points on delivery of large naked DNA molecules into patients 
using physical methods will be covered. Emphasis will be given to ex vivo transfer of 
genomic constructs to cultured mammalian cells and nucleofection and bactofection as two 
promising methods for delivering large constructs will be analyzed. A review of all 
available vectors that allow extra-chromosomal maintenance of foreign DNA will be 
provided with an emphasis on the structure and potential application of EBV-based 
episomes, Human Artificial Chromosomes and Scaffod/Matrix Attachment Region (S/MAR) 
vectors as examples of non-integrating extra-chromosomally retained vectors. In addition, 
two systems for targeted integration at specific sites not associated with carcinogenesis will 
be described. The availability of powerful recombination-based methods for manipulating 
large vectors, a process called recombineering, will also be covered. Finally, an example on 
the development of genomic DNA containing vectors for gene therapy of Cystic Fibrosis 
using recombineering will be given.  
2. Advantages of use of genomic constructs in gene therapy  
The argument for using genomic constructs rather than cDNA in gene therapy is that they 
contain all the introns and flanking DNA which can confer full control of gene expression. 
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Inclusion of introns also allows correct function of genes that encode for different products 
through differential splicing, such as the immunoglobulin genes. Promoters that lie in the 
flanking DNA could be cloned and used in a cDNA construct. However, the introns and 
flanking DNA also contain other elements that can participate in the control of chromatin 
condensation and therefore influence gene expression. The most important of these 
elements are simple enhancers and locus control regions (LCRs) (Lipps et al., 2003). 
Enhancers increase transcription independently of orientation and distance. They can 
suppress silencing of transgenes that is usually observed when integration occurs in a 
condensed and therefore repressive heterochromatin region, a phenomenon called position 
effect (Martin & Whitelaw, 1996). Moreover, they can target transgenes to transcriptionally 
active nuclear compartments and prevent their localization near heterochromatin 
(Francastel, et al., 1999). LCRs are more complex and contain enhancers (Li et al., 1999). A 
general characteristic they have is the presence of DNAse I hypersensitive sites (DHS), 
where chromatin is not condensed and transcription factors can bind to their cognate 
sequences allowing transgene expression. 
The importance of using genomic constructs rather than cDNA or mini-genes has been 
shown for several genes, both in cultured cells and in transgenic mice. Generally, the 
presence of promoters, enhancers, LCRs and other elements, located 5’ or 3’ of the gene or 
within introns, resulted in position-independent expression of the transgenes in the correct 
tissue, at proper levels and right times in contrast to the use of small transgenes carrying 
heterologous promoters. For example transgenic mice generated with long constructs that 
included all the known DHS 5’ of the class II MHC Ea gene showed position-independent, 
copy number dependent expression of Ea. Shorter constructs lacking some of the DHS were 
subject to position effects (Carson & Wiles, 1993). Similar results were obtained when a 250-
kb YAC carrying the genomic locus of the mouse tyrosinase gene was used to generate 
transgenic mice. The transgene was expressed at levels comparable to the endogenous gene, 
in the right tissues and proportional to copy number but independent of position (Schedl et 
al., 1993). Physiological expression of the human Huntington Disease gene has also been 
achieved from a YAC in transgenic mice containing a targeted disruption of the endogenous 
gene.  Huntigtin is essential for development since its absence is lethal in mice but the 
human transgene was expressed in the correct tissue, at adequate levels and early enough in 
development to rescue the mice from embryonic lethality (Hodgson et al., 1996). Likewise, 
the human Friedrich ataxia (FRDA) gene expressed from a 188-kb BAC has been shown to 
rescue FRDA knockout mice from embryonic lethality (Sarsero et al., 2004). Transgenic mice 
were also generated with constructs covering the human β-globin locus, which is a model 
system for studying developmental regulation of gene clusters. The locus consists of five 
genes, ε, Gγ, Aγ, δ and β, the expression of which is tightly regulated both temporally and 
spatially. ε-globin is expressed at embryonic stages,  Gγ- and  Aγ- in the fetal liver and δ- and 
β-globin in the bone marrow of adults. An upstream LCR and a downstream DHS seem to 
control the expression of the genes. Transgenic mice generated by using a 160-kb BAC 
containing the entire human β-globin locus, exhibited proper developmental regulation and 
tissue specific expression of the globin genes (Huang et al., 2000). Interestingly, expression 
of a human BCL2L10 (Boo) BAC transgene targeted at the HPRT locus in transgenic mice, 
followed the human pattern. Human Boo mRNA was detected in organs that had no murine 
Boo mRNA but were known to host Boo expression in humans, suggesting that human 
regulatory elements which were present in the BAC and absent in the mouse endogenous 
gene could drive tissue-specific expression in the mouse background (Heaney et al., 2004). 
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Transgenic work has also been carried out with respect to cystic fibrosis (CF). The disease is 
caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) 
which is normally expressed in specific tissues and shows precisely regulated expression 
thanks to some DHS that are found as far as 80 kb upstream of the first exon (Smith, et al., 
1995). Previous experiments with small mini-gene constructs that obviously could not cover 
the whole genomic region showed some expression of CFTR in transgenic mice (Alton et al., 
1993; Hyde et al., 1993) and low levels of transient correction in CF patients (Caplen et al., 
1995). However, such constructs were not expressed sufficiently in the appropriate tissues to 
achieve clinical improvement in patients. A 320-kb YAC carrying the human CFTR gene 
rescued CFTR null mice (Manson et al., 1997). Gene expression followed the wild type 
mouse pattern except in some tissues such as the pyloric glands, Brunner’s glands, 
epididymis and sublingual glands, presumably due to absence of a distant DHS in the YAC 
or lack of recognition of the human control elements by mouse transcription factors. More 
recently, correct temporal and spatial expression of the human COL6A1 gene (Xing et al., 
2007), the human Brain-Derived neurotropic factor (BDNF) gene (Koppel et al., 2009) and 
the porcine Growth Hormone gene (Tong et al., 2010) has been demonstrated in BAC 
transgenic mice.  
The ability of genomic constructs to drive tissue- and time-specific expression, unlike cDNA 
and mini-genes, has made BAC transgenics an additional tool to knockout transgenics for 
the identification of potential regulatory elements within the locus of a gene. For instance, 
an enhancer within the locus of the tyrosinase-related family (Tyrp1) gene (Murisier et al., 
2006) and a region responsible for tissue-specific expression within the locus of the 
Neurogenin1 gene (Quiñones et al., 2010) have been discovered in transgenic mice generated 
with BACs. 
3. Delivery of large DNA molecules   
Gene therapy with large genomic constructs cloned on BAC vectors unavoidably raises the 
issue of delivery into target cells. The majority of recombinant viruses, commonly utilized as 
carriers for transfer of plasmid DNA, apart from evoking unwanted immune responses, 
have a maximum packaging capacity and cannot be used to deliver large BACs. An 
exception to this rule is the Herpes simplex virus 1 (HSV-1) -derived amplicon vector, which 
has been shown to be able to accommodate and deliver large BACs of up to approximately 
150 kb in size (Wade-Martins et al., 2003). However, even this promising vector is based on 
viral sequences and is subject to criticism regarding its safety. Therefore, delivery of 
genomic loci of therapeutic genes should preferably be non-viral.  
Irrespective of their size, naked DNA molecules are difficult to transfect into cells both in 
vivo and in vitro due to a series of barriers related to almost all aspects of cellular biology. 
Such barriers include degradation by nucleases present in the blood and the extracellular 
matrix, the plasma membrane, transformation of endosomes to digestive lysozomes 
following endocytosis and the nuclear envelope (Al-Dosari & Gao, 2009). Several physical 
methods have been employed to facilitate transfer of naked DNA into cells with efficiencies 
that in some cases resemble those of viral methods. In parallel, chemical methods based 
mostly on cationic lipids and polymers have been developed and used for in vitro and in vivo 
gene transfer. However, the vast majority of published data concern delivery of plasmid 
DNA and further evaluation of both physical and chemical methods for the delivery of large 
BACs is required.     
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3.1 Physical methods for direct delivery to patients 
Physical methods facilitate entry of naked DNA into the cells by creating temporary 
microdisruption of the cell membrane due to physical forces, such as hydrostatic pressure, 
electric pulse, ultrasound, laser irradiation, magnetic fields and particle bombardment. As of 
March 2011, naked plasmid DNA has been used in 18.7% (n=319) of clinical gene therapy 
trials (http://www.wiley.com/legacy/wileychi/genmed/clinical/).    
3.1.1 Injection 
In early experiments, naked plasmid DNA (or RNA) was injected directly into different 
organs of different animals and expression of reporter genes was detected at the sites of 
injection. In mice, this method was used to deliver and express reporter genes in several 
organs including skeletal muscle (Wolff et al., 1990) and lung (Meyer et al., 1995). 
Subsequently, expression of therapeutic genes has been achieved using this method and 
some human clinical trials for limb ischemia (Morishita et al., 2010), erectile dysfunction 
(Melman et al., 2007), Duchenne/Becker muscular dystrophy (Romero et al., 2004)) have 
been based on naked DNA injection into tissues. Although these were phase I or IIa trials 
aiming mostly at assessing safety, some transgene expression and clinical improvement has 
been shown but the level of expression was low.   
A non-invasive alternative to conventional needle injection is jet injection. This technology is 
based on a high velocity narrow jet of liquid containing the DNA, which is able to penetrate 
the skin and underlying tissues. It is powered by compressed air and penetration in a 
specific tissue can be controlled by adjusting the air pressure. So far, the major application of 
jet injection has been the development of DNA vaccines (Raviprakash & Porter, 2006). 
Thanks to technical improvements, the efficiency of delivery by jet injection has reached that 
of other non-viral methods and has been evaluated recently in a clinical trial on patients 
with melanoma and breast cancer (Walther et al., 2008).  
Further progress in the field has led to the development of the so-called hydrodynamic 
injection, which is considered to be the most efficient non-viral gene delivery method in 
mice (Al-Dosari & Gao, 2009). According to the hydrodynamic method, a high volume 
saline solution of plasmid DNA is injected into the tail vein at high velocity. Initial studies 
have shown that this results in high levels of gene expression in the liver (Liu, et al., 1999; 
Zhang et al., 1999). The hydrodynamic injection into the tail vain has also been shown to 
work relatively well with large BAC DNA (Hibbitt et al., 2007; Magin-Lachmann et al., 
2004). Moreover, local hydrodynamic delivery into rabbit liver using catheter-assisted 
perfusion (Eastman et al., 2002) and pressure-mediated delivery to rat kidney (Maruyama et 
al., 2002) and to limb muscle of mammals (Hagstrom et al., 2004) have been achieved. it 
remains to be seen whether similar hydrodynamic methods could be deployed in human 
patients. 
3.1.2 Electroporation 
In vivo electroporation is the application of electrical pulses following local injection of DNA in 
the target tissue. This temporarily increases the cell membrane permeability and facilitates 
DNA uptake by a mechanism that remains unclear. Under optimal conditions the efficiency of 
plasmid DNA delivery by in vivo electroporation can approach that of viral methods but the 
efficiency decreases when larger DNA molecules are used. By using a variety of electrodes, 
ranging from needle to surface electrodes, electroporation has been shown to be effective at 
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delivering small in size DNA to several tissues including muscle and lung (Brown et al., 2008; 
Dean et al., 2003). On the other hand, only few data is available about in vivo electroporation of 
large DNA molecules. In one study, efficient delivery of an 80-kb BAC into electroporated 
muscle has been achieved but, as expected, reporter gene expression from the BAC was found 
5-fold less efficient than from a plasmid (Magin-Lachmann et al., 2004). Increasing knowledge 
and technological progress in electroporation has resulted in its clinical application in humans 
for the treatment of melanoma (Daud et al., 2008) and in several ongoing clinical trials for the 
treatment of other cancers and for DNA vaccination. 
3.1.3 Sonoporation 
Sonoporation is a technique that uses ultrasound waves of high intensity and low frequency 
to cause the same effect on the plasma membrane as electroporation that is transient 
permeabilization in order to facilitate the delivery of DNA into cells. The mechanism is 
different to electroporation though. Ultrasound is believed to result in acoustic cavitation 
that can disrupt temporarily the cell membrane. When it is used in combination with 
microbubbles, which are gas-filled vesicles coated with albumin, polymers or 
phospholipids, cavitation and therefore local DNA uptake are enhanced (Wells, 2004). Such 
microbubbles are commercially available and their stability has been shown to affect directly 
the efficiency of in vivo sonoporation (Alter et al., 2009). 
Several studies have shown in vivo delivery of plasmids carrying either reporter or 
therapeutic genes to different tissues including lung, heart and muscle (Xenariou et al., 2010; 
Alter et al., 2009; Sheyn et al., 2008) but comparative data, wherever provided, confirmed 
that the efficiency of sonoporation was significantly lower than that of electroporation. 
However, sonoporation is still being considered for clinical application in humans due to its 
non-invasive nature and lesser tissue damage caused compared to electroporation. 
Interestingly, a combination of electric pulses and ultrasound waves (electrosonoporation) 
for gene transfer into the skeletal muscle of mice showed 8-fold and 1.6-fold higher gene 
expression compared with electroporation and sonoporation alone, respectively (Yamashita 
et al., 2002). 
3.1.4 Other physical methods 
Particle bombardment via a gene gun, originally designed for DNA delivery in plants, is a 
non-viral gene transfer method based on gold particles coated with DNA. The particles are 
accelerated by pressurized gas and expelled onto tissues. This technique, also referred to as 
ballistic DNA delivery, has been used to deliver transgenes to skin, liver and muscle tissues 
of rats and mice (Yang et al., 1990) and DNA vaccines to skin, muscles and tumours in 
animal models and in human clinical trials. Recently, is has been shown to be efficient at 
delivering a small reporter gene to mouse liver in vivo (Chang et al., 2008). Almost no data is 
available on the ability of gene gun to deliver large DNA constructs in vivo. In just one 
study, a DNA vaccine containing a 183-kb BAC has been delivered using gene gun and has 
been shown to confer immune protection to chickens (Tischer et al., 2002). 
A new promising method of gene transfer based on the utilization of infrared laser beam has 
been developed and used to deliver a small transgene to mouse muscle in vivo (Zeira et al., 
2003). This study reported efficiency of delivery, assessed by measuring the intensity and 
duration of transgene expression, equal to that by electroporation but with less damage 
caused to the tissue. 
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Finally, magnetic fields have been used to enhance in vivo targeted gene delivery.  In this 
method, called magnetofection, the DNA is reversibly coupled to superparamagnetic 
nanoparticles which are directed to the target site, following local injection, via a high-
energy magnetic field. In vivo magnetofection has been shown to work for small in size 
plasmid DNA delivery to the gastrointestinal tract of rats and the blood vessels of the ear of 
pigs (Scherer et al., 2002) and the respiratory epithelium of mice (Xenariou et al., 2006).  
3.2 Chemical methods for direct delivery to patients 
Chemical vectors used for gene delivery present a broad diversity, with hundreds of 
different reagents being available (Al-Dosari & Gao, 2009), but generally fall into two main 
categories: cationic lipids and cationic polymers. These act by forming complexes with the 
negatively charged DNA, named lipoplexes and polyplexes respectively, which protect the 
DNA from nucleases and allow its entry into the cells by endocytosis, pinocytarosis or 
phagocytosis and its transfer into the nucleus by escaping of the complexes from the 
endosomes following their internalization. The mechanism by which these processes take 
place are different for lipoplexes and polyplexes and the overall efficiency depends on the 
chemical structure of the cationic lipids/polymers, the charge ratio between the cationic 
lipids/polymers and the DNA, the size and structure of the lipoplexes/polyplexes and  
the inclusion of helper lipids such as DOPE and cholesterol in the complexes (Tros de 
Ilarduya et al., 2010). 
Over the years many cationic lipids showing high transfection efficiency were developed 
and lipofection has become the most common method for gene transfer in vitro. 
Unfortunately, lipoplexes are not equally good for in vivo delivery as most of them are 
inactivated after interaction with factors present in the blood. However, successful in vivo 
DNA delivery has been reported both with systemic and local administration. A single 
intravenous injection of lipoplexes into mice has been shown to result in reporter transgene 
expression in the lung, heart, liver, spleen, and kidney (Song et al., 1997). Impressively, local 
administration of cationic lipid/CFTR-plasmid-DNA complexes in an aerosol formulation  
to the lungs of cystic fibrosis transgenic mice resulted in correction of the ion transport 
defect (Hyde et al., 1993). Similar studies in human patients demonstrated some transgene 
expression but not at sufficient levels to provide a clinical benefit (Griesenbach and  
Alton, 2009).  
Apparently, the choice of the cationic lipid to be used depends on the application and 
careful optimization of the transfection protocol is required considering that lipoplexes can 
also induce unwanted immune responses. Lipofection has been used in 6.4% (n=109) of gene 
therapy clinical trials (http://www.wiley.com/legacy/wileychi/genmed/clinical/). 
There has also been an extensive use of cationic polymers in DNA delivery studies with 
polyethylenimine (PEI) being the most active reagent. Polyplexes are more stable than 
lipoplexes and their toxicity and transfection activity depend on their molecular weigh 
(mw). Polymers with low mw are more efficient and less toxic than those with high mw 
(Fischer et al., 1999). Interestingly, intravenous injection of PEI/BAC-DNA complexes in 
mice has been found to be less efficient than other non-viral gene delivery methods such as 
electroporation and hydrodynamic injection (Magin-Lachmann et al., 2004).  
3.3 Ex vivo delivery to cells 
An alternative to in vivo delivery of DNA for gene therapy is the ex vivo approach. This 
procedure consists of surgically removing target cells from a patient, transducing them with 
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an appropriate therapeutic gene in culture and then reimplanting them into the body of the 
donor. Since it involves the use of autologous cells, there is no need for immunosupression 
following transplantation of the cells back to the patient. In most ex vivo gene therapy 
applications, transplanted cells need to integrate into the appropriate tissue and the 
efficiency of this “homing” process is tissue type-dependent.  
Recent progress in stem cell research has revolutionized ex vivo therapy. Stem cells are 
characterized by their ability to differentiate into a diverse range of cell types when placed 
in the appropriate environment both in vitro and in vivo and can therefore be used directly  
in cell therapy (Abdulrazzak et al., 2010). An ex vivo cell therapy approach using Embryonic 
Stem Cells or foetal Mesenchymal Stem Cells would not involve transfection of a therapeutic 
gene and would overcome the low gene delivery efficiency hurdle. However, it would  
have to be used in an allogeneic fashion which would bring the need for using 
immunosuppressive drugs. A more attractive strategy would be the transfer of a therapeutic 
gene to patient-derived autologous stem cells such as Mesenchymal Stem Cells (MSCs) 
which can easily be isolated from the bone marrow or adipose tissue of adults and have 
been shown to have an excellent differentiation potential (Abdallah & Kassem, 2008) or 
Induced Pluripotent Stem Cells that can be generated by reprogramming of adult somatic 
cells (Yu et al., 2007; Takahashi et al., 2007). 
Several non-viral methods have been utilized to transfer DNA into MSCs for ex vivo gene 
therapy purposes. The aim of the following sections is to review two of them, nucleofection 
and bactofection. The criteria for this choice are their ability to deliver very large DNA 
molecules intact and/or maintain the differentiation potential of the MSCs following 
transfection.   
3.3.1 Nucleofection 
Nucleofector technology developed by Amaxa Biosystems is a non-viral method of gene 
transfer based on electroporation using a combination of electrical parameters and solutions 
that are specific for each cell type. Unlike other non-viral transfection methods, it facilitates 
the transfer of DNA directly into the cell nucleus. It is particularly useful for gene transfer 
into a variety of primary cell types from different species which are normally very difficult 
to transfect (Gresch et al., 2004). 
 Nucleofection has been shown to be able to efficiently deliver plasmid DNA carrying a 
reporter gene to MSCs without impairment of their differentiation capacity (Aluigi et al., 
2006). Preliminary data on stable cell lines generated by nucleofection with large BACs 
suggest that nucleofection can also be used to deliver genomic constructs but does not result 
in all clones containing intact and unrearranged DNA (Cheung et. al., unpublished data).   
3.3.2 Bactofection 
Direct delivery of DNA into mammalian cells by invasive bacteria (bactofection) is 
another potentially useful technique for gene transfer and it may have applications for 
both in vitro and in vivo delivery (Larsen et al., 2008). In this method, the DNA is first 
introduced either in the form of a plasmid or a BAC into bacteria having the ability to 
invade eukayotic cells and subsequently these bacteria are used to invade and deliver 
their DNA content into target cells. Several bacterial systems allowing eukaryotic cell 
invasion have been described. The most convenient is based on the the E. coli strain 
BM4573 (Laner et al., 2005). BM4573 bacteria have been modified to 1) stably express 
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invasin, from the inv gene of Yersinia pseudotuberculosis, which binds to β1-integrins on 
mammalian cells leading to internalization, 2) have permanent impaired cell wall 
synthesis due to diaminopimelic acid (DAP) auxotrophy which causes bacterial lysis 
following internalization and 3) stably express listeriolysin O, from the hly locus of Listeria 
monocytogenes, which is a pore-forming cytolysin that allows escape from the vacuole after 
bacterial entry and release of the DNA into the cytosol resulting in greater levels of 
transgene expression (Laner et al., 2005).  
One advantage of the method is that there is no need to purify the DNA prior to 
transfection, which is still a technically challenging procedure for very large DNA 
molecules. Another advantage is that DNA delivered by bacterial invasion is rarely 
rearranged. Rearrangements are always an issue of concern when using other DNA delivery 
methods to transfer large BACs. For instance, although lipofection and electroporation have 
been used to efficiently deliver large BAC DNA into cultured cells, some of the clones 
generated have been shown to suffer from rearrangements (Magin-Lachmann et al., 2004; 
Cheung et al., unpublished data). In contrast, several studies have demonstrated that large 
BACs are delivered intact by bacterial invasion albeit with low efficiency. In two of them, 
stable cell lines containing integrations of a ~250-kb BAC carrying the human clotting factor 
VIII (FVIII) gene (Pérez-Luz et al., 2007) and of a ~258-kb BAC carrying the human CFTR 
gene (Kotzamanis et al., 2009) have been generated by bacterial invasion. No clones have 
been found to contain rearranged DNA in any of the two studies and expression of the 
respective transgenes has also been shown in both of them. Therefore, bactofection is an 
attractive method for delivering large genomic DNA containing intact constructs. The ability 
of the method to deliver large BACs into MSCs without affecting their differentiation 
potential is yet to be shown.  
4. Extra-chromosomal vectors 
Regardless of the type and size of the therapeutic gene (small cDNA versus large genomic 
DNA) and the delivery method (viral versus non-viral) to be used in a gene therapy 
protocol, efficient retention and long-term expression of the transgene is required so as to 
eliminate the need for re-administrations. Integration into the host genome has widely been 
used in gene therapy to fulfil this requirement. However, the dangers of integration due to 
insertional mutagenesis have become a widely publicised issue as a result of a clinical trial 
using a retroviral vector to treat X-linked severe combined immune deficiency (SCIDX1). In 
this trial some patients developed leukaemia due to deregulation of the growth-promoting 
LIM domain only 2 (LMO2) proto-oncogene caused by integration of the vector (Hacein-
Bey-Abina et al., 2003a, 2003b). The safety concerns regarding uncontrolled integration of 
the therapeutic gene into the host genome have been strengthened by observations that 
there is a preference of integrating vectors for the regulatory regions of transcriptionally 
active genes (Bushman et al., 2005). Given the need for long-term expression and the 
problems associated with vector integration, vectors that persist in the nucleus by being 
maintained episomally without integrating could be highly advantageous. Three different 
systems have been employed to achieve extra-chromosomal maintenance of the vectors 
carrying the therapeutic gene: systems based on elements from the Epstein-Barr virus (EBV), 
artificial chromosomes and systems based on scaffold/matrix attachment region (S/MAR). All 
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4.1 OriP/EBNA-1 episomal vectors 
The best characterized system for episomal maintenance is based on sequences derived from 
the EBV genome. EBV is a member of the herpesvirus family with a 172-kb genome that is 
latently maintained as an independently replicating episome in a small percentage of 
infected lymphocytes (Masucci & Ernberg, 1994). During the latent phase of its cycle, DNA 
replication occurs from the origin of replication oriP and only about 10 proteins are 
produced of which the only protein that is required for replication at oriP is the Epstein Barr 
Nuclear Antigen-1 (EBNA-1) (Yates et al., 1985). The interaction of oriP with EBNA-1 also 
enables the segregation of the viral genome between the daughter cells through the 
association of EBNA-1 with host metaphase chromosomes (Harris et al., 1985).  
These features of the EBV have been exploited to develop a system for episomal 
maintenance of foreign DNA delivered into cells. It has been shown that plasmids carrying 
oriP and expressing EBNA-1 can replicate autonomously once per cell cycle when delivered 
into human cells and can segregate by attaching to the host chromosomes (Haase & Calos, 
1991). The oriP/EBNA-1 system has also been shown to support long-term episomal 
maintenance without selection and expression of very large human genes, such as the CFTR 
(Huertas et al., 2000), the human hypoxanthine phosphoribosyltransferase (HPRT) (Wade-
Martins et al., 2000) and the β-globin gene (Black & Vos, 2002). Following these promising 
results, a convenient system for adding the oriP/EBNA-1 sequences onto any BAC already 
containing a therapeutic gene has been developed (Magin-Lachmann et al., 2003) and will be 
analyzed  later on. 
The oriP/EBNA-1 retention system is easy to use and can provide extra-chromosomal 
maintenance to foreign DNA of hundred kilobases delivered into cells but has some major 
disadvantages. It provides random rather than equal segregation of the episomal vector to 
daughter cells which results in loss of the episomes at a rate of 2-8% per cell division 
(Sclimenti & Calos, 1998). This, along with the fact that it involves viral sequences 
particularly from the EBV which has been associated to several types of human 
malignancies (Cohen, 2000) limits the use of EBV vectors for safe gene therapy.  
4.2 Human artificial chromosomes 
Human Artificial Chromosomes (HACs) are vectors able to replicate and segregate in 
parallel with the endogenous chromosomes in human cells. To achieve this, they must 
contain the minimal elements required for chromosome function, namely an origin of 
replication, telomeres and centromeres (Pérez-Luz & Díaz-Nido, 2010).  
One approach towards constructing HACs, called “top-down”, involves fragmentation of 
already existing chromosomes and generation of smaller mini-chromosomes, where only the 
three functional chromosomal elements remain. Several studies have shown that mini-
chromosomes can host and allow the expression of large therapeutic genes, be transferred 
between various mouse and human cell lines and be transmitted through the mouse germ 
line (Kakeda et al., 2005; Shen et al., 2001; Voet et al., 2001). Though mini-chromosomes have 
useful properties for application in transgenics, their use in gene therapy is restricted to an 
ex vivo approach only. 
HACs with a high potential for use in in vivo gene therapy are generated by a different 
approach named the bottom-up. This is similar to the method applied for YAC construction 
in yeast and involves assembling the functional chromosomal elements and building up a 
HAC de novo in human cells. Different strategies have been followed to generate de novo 
HACs, the most convenient of which is to transfect a BAC carrying only a large array of α-
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satellite (alphoid) DNA and some marker genes into HT1080 cells. No telomeric sequences 
or an origin of replication have been shown to be required, probably due to generation of 
circular HACs and initiation of replication at origins found within the marker genes 
(Ebersole et al., 2000). HACs generated this way exist as single (or low copy) chromosomes 
in the nucleus and have a high mitotic stability (close to 100%) in the absence of selection. 
The potential use of these vectors in gene therapy has been demonstrated by expression of 
large therapeutic genes from them (Grimes et al., 2001; Mejía & Larin, 2000). Further 
advance was noted when efficient methods for manipulating large sequences of repetitive 
nature, such as alphoid DNA, were developed and used to generate HACs, as will be 
discussed later on (Kotzamanis et al., 2005). Nevertheless, several issues need to be solved 
before any clinical application. First, HACs have been shown to form efficiently only in 
HT1080 cells so far. Whether this is due to their inability to form in other cell lines has not 
been answered yet, but is limiting their use for in vivo gene therapy. Second, all HACs 
produced by de novo synthesis in HT1080 cells have been between 1 and 10 Mb in size, 
definitely smaller than native chromosomes, but larger than the input DNA, suggesting that 
unpredictable amplifications and rearrangements have occurred during their formation, 
which is not desired for safe gene therapy vectors. Third, other fates of the input DNA than 
formation of HACs have been observed and integration has not been excluded (Harrington 
et al., 1997). This would not be a problem in ex vivo therapy where individual clones 
expressing the gene of interest from a HAC could be isolated, but in in vivo gene therapy, 
any interaction of the input DNA with the endogenous chromosomes could have the same 
consequences as viral vectors have. Further research is necessary to increase the efficiency of 
HAC formation so as to ensure that no integration events take place. 
4.3 S/MAR vectors 
S/MARs are diverse sequences found in all eukaryotic genomes where they are involved in 
many aspects of chromatin function such as organization of chromatin into loops, which 
seems to be mediated by the interaction between S/MARs and the nuclear matrix (Heng et 
al., 2004). Experiments with a plasmid vector containing an S/MAR element isolated from 
the human interferon β- gene has revealed one more feature of S/MARs, their ability to 
provide episomal maintenance of foreign DNA introduced into cells. This vector was able to 
replicate and remain episomally in CHO cells at low copy number for more than 100 
generations in the absence of selection and with a mitotic stability of 98% (Piechaczek et al., 
1999). It was later confirmed that the mitotic stability of the vector was provided through 
the interaction of the S/MAR with the nuclear matrix (Baiker et al., 2000). Interestingly, the 
S/MAR used seemed to prevent vectors from integrating into the host genome as integration 
events were observed in less than 1% of stably transfected clones (Jackson et al., 2006). The 
ability of the interferon β S/MAR to provide replication and episomal retention has been 
demonstrated in several cell lines and in primary cells (Papapetrou et al., 2006) and also in 
vivo in genetically modified pigs (Manzini et al., 2006). Furthermore, the same S/MAR 
element has been introduced by site-specific homologous recombination to a BAC carrying 
135 kb of the human low density lipoprotein receptor (LDLR) genomic locus and shown to 
provide low copy episomal maintenance in CHO ldlr-/- cells for more than 100 generations 
without selection and long-term expression of the transgene at high enough levels to 
completely restore LDLR function in these cells (Lufino et al., 2007).  
In summary, it seems that unlike viral episomal vectors which need to encode viral factors 
required for their function, S/MAR vectors achieve their replication and segregation by 
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recruiting and interacting with host cell proteins. Moreover, unlike HAC vectors, S/MAR 
vectors do not need to undergo amplifications and rearrangements to function and are 
therefore of defined structure and composition. These unique safety properties of S/MARs 
make them very attractive for use in gene therapy with large genomic constructs.      
5. Vectors integrating at specific sites 
An alternative to the use of episomal vectors described above, that still satisfies both 
requirements for permanent transgene expression and elimination of genotoxic effects is the 
controlled integration of the therapeutic construct at a specific site in the host genome where 
no active genes are present. Several vector systems have been developed to achieve this, 
with each one of them having its own limitations (Voigt et al., 2008). From this variety of 
available vectors, only two types will be described based on their preference for specific 
sequences that already exist in the human genome, their potential for in vivo use and their 
ability to support integration of large genomic constructs.   
5.1 Phage integrase based vectors 
The Streptomyces phage ΦC31 integrase is an enzyme that can catalyze site-specific 
recombination between a phage attachment site (attP) and a bacterial attachment site (attB) 
resulting in integration of ΦC31 into the bacterial genome and initiation of the lysogenic 
phase of its life cycle (Groth & Calos, 2004). This integrase has been shown to be able to 
irreversibly integrate a single copy of foreign DNA, containing the attP site, into the human 
genome at native pseudo att sites found in the intergenic regions on human chromosomes 
and far from known oncogenes (Chalberg et al., 2005). 
A series of studies have validated the potential of ΦC31 integrase-based vector systems in ex 
vivo gene therapy by demonstrating expression of different therapeutic genes in cultured 
cells including human embryonic stem cells (Thyagarajan et al., 2008) and  in in vivo gene 
therapy by showing expression of different therapeutic genes in animal models, like  
the dystrophin gene in dystrophic mouse muscle (Bertoni et al., 2006). Evidence that the 
system can be used in gene therapy with genomic constructs has been provided by 
transgenic work in Drosophila, where the ΦC31 integrase has been used to integrate large 
DNA fragments of up to 133 kb into the genome (Venken et al., 2006). However, other 
studies have questioned the safety of such vectors by showing that stably expressed ΦC31 
integrase could cause numerous chromosomal abnormalities in human cells (Liu et al., 2006) 
and that in some cases ΦC31-mediated integration is associated with chromosome 
rearrangements, probably due to recombination between cryptic att sites (Ehrhardt et al., 
2006). Recently developed mutational derivatives of ΦC31 integrase that have higher 
integration efficiency and specificity, may eliminate the safety concerns for its use in gene 
therapy (Keravala et al., 2009). 
A very similar approach for site-specific integration is based on the utilization of 
transposase enzymes, with the Sleeping beauty and the piggyBac being the most thoroughly 
studied, which allow for the integration of foreign genes into genomic regions containing 
transposable elements. (Ivics & Izsvak, 2010). However, such systems are unlikely to prove 
useful for integration of large genomic constructs as their ability to transpose is significantly 
decreased when the insert length is increased, a phenomenon called “length-dependence” 
(Atkinson & Chalmers, 2010).   
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5.2 Adeno-associated virus based vectors 
Some features of the Adeno-associated virus (AAV) can be exploited for site-specific 
integration of foreign DNA. AAV is a non-pathogenic virus with a 4.7 kb single-stranded 
DNA genome comprising two genes, rep and cap flanked by 145 bp palindromic sequences 
termed inverted terminal repeats (ITRs) (Srivastava et al., 1983). In the presence of a helper 
virus such as adenovirus or herpes simplex virus, AAV can undergo replication and enter 
its lytic cycle while in their absence AAV integrates into the human genome and becomes 
latent. The ITRs contain the sequences required for replication, packaging and integration of 
the virus and the rep gene encodes four regulatory proteins required for catalysis of 
integration into the human genome during latency. Integration occurs into a specific site on 
chromosome 19 called the AAVS1 (Kotin et al., 1992).  
It has been shown that human transgenes flanked by ITRs can integrate into the AAVS1, 
with the minimal requirement for expression of viral Rep in cultured human cells  
(Cortés et al., 2008), and in vivo in transgenic mice carrying the human AAVS1 (Liu et al., 
2010; Recchia et al., 2004) . The AAV system has also been shown to be able to integrate 
large genes of 100kb in size into the AAVS1 (Oehmig et al., 2007). These studies have 
demonstrated the effectiveness of AAV-based vectors but again safety issues have emerged. 
Integration of small transgenes has been detected in 10-30% of infected human cells in 
culture with only about half of the integrations occurring specifically at the AAVS1 (Recchia 
& Mavilio, 2006), suggesting that there would be a 50% probability of insertional 
mutagenesis in a gene therapy application. In addition, persistent expression of the viral 
Rep protein is toxic and can cause chromosome instability and mobilisation of the transgene 
(McCarty et al., 2004).   
6. Methods for modification of large DNA molecules 
Gene therapy using genomic constructs entails engineering of large DNA fragments often of 
repetitive nature. For instance, marker genes and other useful sequences, able to confer 
extra-chromosomal maintenance, need to be added to vectors carrying large genomic 
fragments, without causing any rearrangements. In other cases, the entire genomic locus of a 
therapeutic gene may not be available in a single BAC vector and linking of the inserts of 
two or more BACs is necessary. The technical difficulty in performing such manipulations 
has hampered progress in this field for a long time. Only recently, efficient engineering 
methods have been developed allowing the consideration of BACs carrying genomic loci as 
gene therapy vectors.       
6.1 Addition of marker and small genes 
In most cases, the cloning of mammalian selectable markers and small reporter genes on the 
vector region of a BAC carrying a genomic insert by classic molecular biology procedures is 
limited by lack of convenient cloning sites on the vector, the possible presence of many 
restriction sites in the insert and the difficulty in manipulating large DNA molecules 
without affecting their integrity. Alternatives to classic molecular biology techniques using 
restriction enzymes are therefore required. For adding reporter genes and short sequences 
onto BACs, site specific homologous recombination mediated by the bacteriophage P1-
derived Cre/loxP system is such an alternative.  
The Cre protein recognizes and catalyses efficiently recombination only between specific loxP 
sites, which are present on all BAC vectors making a modification method based on them 
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generally applicable. As shown in Figure 1, the first step in such a method is the construction 
of a suitable retrofitting plasmid (pRetro) that carries the gene to be added onto the BAC, a 
loxP site and a selectable marker. Replication of pRetro depends on the high-copy gamma 
origin (γ-ori) that only operates in an E. coli host expressing the pi protein (product of the pir 
gene). Following insertion of the plasmid into the BAC in the DH10B E. coli host which does 
not express pi, the γ-ori becomes not functional and the BAC remains low-copy. The system 
shown in Figure 1 uses a separate plasmid to express Cre that is co-transfected with the 
retrofitting plasmid and then lost once retrofitting has occurred without being involved in the 
recombination process as it does not have a loxP site (Mejía & Larin, 2000). This plasmid 
contains a LacZ-cre fusion gene so that Cre is expressed after IPTG induction and also a 
temperature sensitive origin of replication that is functional only at 300C. As shown in Figure 
1, in vivo retrofitting of the BAC with pRetro occurs at 300C and then bacteria are grown at 
420C so that the Cre expressing plasmid is lost to avoid any further unwanted recombination 
events. Various pRetro plasmids for conveniently adding a G418 mammalian selectable 
marker, a GFP reporter gene, a luciferase reporter gene and/or an OriP/EBNA-1 element onto 
any BAC have been made available (Magin-Lachmann et al., 2003).  
 
 
Fig. 1. Addition of small marked/reporter genes onto BACs by Cre/loxP recombination 
6.2 Addition of large sequences 
The construction of a genomic DNA-containing gene therapy vector with the ability to 
remain extra-chromosomally may involve the addition of large stretches of DNA that are 
difficult to clone into a pRetro plasmid in order to add them to a BAC by Cre/loxP 
recombination, as described in the previous section. For example, a 70-kb alphoid array has 
been shown to be required so as to enable a PAC vector to form HACs in HT1080 cells 
(Ebersole et al., 2000). For such applications, a method for manipulating large segments of 
DNA, based on homologous recombination in E. coli and termed recombineering, has been 
developed (Copeland et al., 2001). In recombineering, the sequence to be introduced is 
flanked by two regions of homology to the BAC, the length of which depends on the 
recombination system that catalyzes the recombination reaction. A selectable marker is also 
included in most applications so as to allow selection for correctly retrofitted clones in E. 
coli. The phage recombination systems RecET and Red consist of genes encoding proteins 
involved in homologous recombination of cryptic Rac prophage and bacteriophage 
λ respectively. These systems are relatively efficient, do not require long homology regions 
and rarely catalyze unwanted recombination events when used in recombineering (Court et 
al., 2002; Muyrers et al., 2001). Particularly the Red recombination system has been used to 
introduce a 70-kb alphoid array into a BAC, carrying a 156-kb genomic insert containing the 
HPRT gene, by recombineering (Figure 2) and expression of the HPRT gene from generated 
HACs has been demonstrated (Kotzamanis et al., 2005). As shown in Figure 2, 
recombination was targeted to the chloramphenicol resistance gene which is present on all 
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BACs, allowing for the addition of the 70-kb alphoid array into any BAC and subsequent 
formation of HACs in the appropriate cells (Kotzamanis et al., 2005). 
 
 
Fig. 2. Addition of large arrays of alphoid DNA onto BACs by recombineering 
6.3 Linking of two overlapping BACs 
There are many large human genes which are of the same order of size, or larger, than the 
average insert size of the BAC libraries and for these it is often difficult to find a single BAC 
spanning the entire gene with all its associated controlling elements.  Gene therapy using 
the genomic loci of such genes would require the assembly of different sequences into a 
single BAC clone by linking together all available overlapping BAC clones spanning the 
desired region. Recombineering mediated by the Red system from the λ-prophage has been 
used to link two overlapping BACs (Kotzamanis & Huxley, 2004; Zhang & Huang, 2003) 
and linking has been shown to be precise without causing any rearrangements, including 
shifting of the reading frame of the therapeutic gene (Kotzamanis et al., 2009). As shown in 
Figure 3, the method comprises two rounds of homologous recombination to link the inserts 
of two overlapping BACs. In the first round, the inserts of the BACs are subcloned into 
modified BAC vectors (pBACLink vectors linearized by NotI) by homologous recombination 
at regions indicated as HomA, HomB and HomC (which are PCR amplified and cloned into 
the pBACLink vectors prior to their linearization). In the second round, one of the modified 
BACs is linearized by the rare cutting enzyme I-PpoI and introduced into recombination 
efficient bacteria containing the other modified BAC, resulting in recombination at HomB 
and Cma (part of the chloramphenicol resistance gene present on all BACs) and linking of 
the two inserts in a single BAC. More overlapping BAC inserts can be added by alternating 
use of the two pBACLink vectors described in the study (Kotzamanis & Huxley, 2004). 
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Fig. 3. Linking of two overlapping BACs into a single larger BAC 
7. Towards gene therapy of cystic fibrosis using a genomic construct 
Cystic Fibrosis is the most common genetic disease in the Caucasians caused by mutations 
in the CFTR gene which is 250 kb long and encodes a cAMP regulated transmembrane Cl- 
ion channel in epithelial cells of several organs. The most severe implications which 
eventually lead to death are in the lungs (Boucher, 2002).  
For several reasons including the easy access to the respiratory tract without any 
intervention procedures, the cloning and the characterization of the CFTR gene (Riordan et 
al., 1989; Rommens et al., 1989) and the expectation that even relatively low levels of 
expression of the gene may have a therapeutic outcome (Dorin et al., 1996), Cystic Fibrosis 
became an ideal target for gene therapy.  
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In previous preclinical and clinical studies where CFTR cDNA-heterologous promoter 
systems and different viral vectors were used for the delivery and expression of the 
transgene, some expression has been shown in transgenic mice and low levels of transient 
correction of Cl- ion transport deficiency has been observed in patients but no significant 
clinical improvement has been achieved (Griesenbach & Alton, 2009).  
Due to the strict regulation of expression of the CFTR gene at specific developmental stages 
and in specific tissues, controlled by regulatory elements found before, after and within the 
gene (McCarthy & Harris, 2005), the use of constructs covering the whole genomic locus of 
the gene may have a better therapeutic potential for Cystic Fibrosis. To date, the only 
transgene that has fully restored transgenic mice, which did not express endogenous 
CFTR and would normally die, is the intact gene present on a YAC of approximately 300 
kb in length (Manson et al., 1997). However, YAC vectors have the disadvantage of being 
difficult to shuttle between cells and are inherently unstable and therefore have been 
replaced by BACs. The CFTR gene is one of the large human genes that have not been 
found to be contained intact in any of the sequenced BACs available from the Human 
Genome Project. For this reason, the technology described in section 6.3 was developed 
and used to construct a BAC vector carrying the whole CFTR gene and the associated 
regulatory elements (Kotzamanis et al., 2009). Successful transcription of the gene to a 
correctly spliced mRNA has been demonstrated in a mouse cell line. This BAC is the only 
CFTR genomic system available on a convenient vector and may be the basis for non viral 
gene therapy for Cystic Fibrosis. 
Viral approaches to gene therapy for Cystic Fibrosis suffer from gene delivery barriers such 
as absence of viral receptors in the respiratory epithelium and safety concerns such as 
provocation of an inflammatory response. This makes either in vivo or ex vivo non viral gene 
therapy an attractive avenue of research. However, several issues need to be solved before 
any clinical application. For instance, the in vivo delivery of non viral vectors is limited by 
the low efficiency, which becomes lower when bigger constructs are used. The 
demonstration that bone marrow-derived MSCs were able to differentiate to several types of 
cells including airway epithelial (Wang et al., 2005) indicated a potential application in an ex 
vivo approach but this is limited by poor data on how the ex vivo corrected MSCs can be 
administered and engrafted in the lung of Cystic Fibrosis patients.  
Ideally, genetic manipulation with the CFTR BAC whether in the form of in vivo or ex vivo 
gene therapy would have to confer permanent transgene expression to avoid repeated gene 
or cell administration, respectively. In this regard, any of the systems that allow episomal 
maintenance or targeted integration at non-associated with carcinogenesis regions 
(described in sections 4 and 5) would have to be added to the CFTR BAC. The methodology 
required to add small sequences such as the OriP/EBNA-1 or the S/MAR elements, or large 
sequences such as the 70-kb alphoid array onto the CFTR BAC is available (see sections 6.1 
and 6.2). Moreover, several methods for either in vivo or ex vivo delivery of the final 
construct to the respiratory epithelium have been developed and are available for use with 
the genomic CFTR-locus containing BAC (see section 3).   
8. Conclusion 
Non-viral gene therapy using the entire genomic locus of the therapeutic gene has two 
advantages over viral cDNA gene therapy; it is not associated with unwanted immune 
responses and can confer controlled levels of transgene expression in correct time and 
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tissue. When combined with a system for extra-chromosomal maintenance or targeted 
integration it can provide permanent transgene expression without causing insertional 
mutagenesis and is therefore considered to be very safe. Among all available systems, the 
S/MAR element seems to be the most efficient, safe and convenient and may also be 
utilized in vivo. The problem of difficulty in manipulating large segments of DNA and  
in delivering them into cells in vitro or in vivo, which has been limiting the use of genomic 
constructs in gene therapy for years, has started finding its solution by the development 
of recombineering and of several physical and chemical methods for gene  
transfer. Apparently, there will not be a delivery system for general use and the choice of 
the most appropriate delivery method will depend on the specific application and gene 
therapy strategy.       
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